In vitro assessment of antifungal drug resistance.
Several studies have documented the variability in the susceptibility pattern of fungi to antifungal drugs, and fungi possess resistance determinants to negate the effects of antifungal agents. In vitro assessment of both resistance and susceptibility are measured by suitable concentration endpoints of the antifungal drug, the minimal inhibitory concentration (MIC). MICs serve as the main parameter to define the fungistatic action on fungi growing in culture. For the antifungals used for treatment of local mycoses, the limit between a MIC value indicating susceptibility and one indicating resistance is usually determined empirically on the basis of the correlation between MIC values, and either positive or negative response to chemotherapy. The principles of susceptibility testing of fungi are essentially the same as those for bacteria. However, testing with fungi must deal with the fact that interpretation of the results is complicated by inherent differences in fungal morphology, growth rate, and optimal culture conditions. Several factors could adversely affect the test results and must be considered in the design of susceptibility testing of fungi. It is obvious when the present data on fungal susceptibility testing are reviewed that much more work on standardization of techniques and interpretation of results is necessary. This presentation will focus on the in vitro susceptibility testing for determining primary and secondary drug resistance of griseofulvin and azole antifungal agents, and the correlation between the activities of these antifungals in vitro and in vivo.
Holmberg
K
K
D000935:Antifungal Agents / Q000627:therapeutic use*; D003022:Clotrimazole / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005658:Fungi / Q000187:drug effects*; D006118:Griseofulvin / Q000627:therapeutic use*; D007093:Imidazoles / Q000627:therapeutic use*; D066298:In Vitro Techniques; D007654:Ketoconazole / Q000627:therapeutic use; D008825:Miconazole / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests / Q000379:methods; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D007093:Imidazoles; D014230:Triazoles; C037815:terconazole; D006118:Griseofulvin; D008825:Miconazole; D003022:Clotrimazole; D007654:Ketoconazole